A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).
Jatin Patel,
Damon Bass,
Albertus Beishuizen,
Xavier Bocca Ruiz,
Hatem Boughanmi,
Anthony Cahn,
Hugo Colombo,
Gerard J Criner,
Katherine Davy,
Javier de-Miguel-Díez,
Pablo A Doreski,
Sofia Fernandes,
Bruno François,
Anubha Gupta,
Kate Hanrott,
Timothy Hatlen,
Dave Inman,
John D Isaacs,
Emily Jarvis,
Natalia Kostina,
Tatiana Kropotina,
Jean-Claude Lacherade,
Divya Lakshminarayanan,
Pedro Martinez-Ayala,
Charlene McEvoy,
Ferhat Meziani,
Mehran Monchi,
Sumanta Mukherjee,
Rosana Muñoz-Bermúdez,
Jessica Neisen,
Ciara O'Shea,
Gaëtan Plantefeve,
Lorrie Schifano,
Lee E Schwab,
Zainab Shahid,
Michinori Shirano,
Julia E Smith,
Eduardo Sprinz,
Charlotte Summers,
Nicolas Terzi,
Mark A Tidswell,
Yuliya Trefilova,
Russell Williamson,
Duncan Wyncoll,
Mark Layton
Nov 16, 2022
BACKGROUND: Granulocyte-macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19. METHODS: In this randomised, sequential, multicentre...